14097-37-1

Upstream product

• 14097-36-0 2-methyl-6-nitro-1,2,3,4-tetrahydro-isoquinoline 
• 164148-92-9 tert-butyl 6-amino-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 1231163-94-2 2-methyl-6-trifluoroacetamido-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 1080645-27-7 azetidine-1,2-dicarboxylic acid-1-[(4-chloro-phenyl)-amide]-2-[(2-methyl-1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide] trifluoroacetate 
• 1080645-31-3 2-methyl-azetidine-1,2-dicarboxylic acid-1-[(4-bromo-phenyl)-amide]-2-[(2-methyl-1,2,3,4-tetrahydro-isoquinolin-6-yl)-amide] trifluoroacetate 
• 895638-08-1 2,2,2-trifluoro-N-[3-(3-{5-fluoro-2-[(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)amino]-4-pyrimidinyl}pyrazolo[1,5-a]pyridin-2-yl)phenyl]acetamide 
• 957469-28-2 benzyl (2S,4R)-4-methoxy-2-methyl-2-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-6-ylcarbamoyl)-pyrrolidine-1-carboxylate trifluoroacetate 
• 957469-32-8 benzyl (2R,4R)-4-methoxy-2-(2-methyl-1,2,3,4-tetrahydro-isoquinolin-6-ylcarbamoyl)-pyrrolidine-1-carboxylate trifluoroacetate 

Relevant academic research and scientific papers

Identification of a series of 1,2,3,4-tethydroisoquinolinylbenzamides with potential anticonvulsant activity

A series of N-(tetrahydroisoquinolinyl)-2-methoxybenzamides was identified by high-throughput screening at the novel SB-204269 binding site. SAR studies have provided compounds 4 and 14 with high affinity and good anticonvulsant activity in animal models.

1, 2 - DIHYDRO- 3H- PYRAZOLO [3, 4 - D] PYRIMIDIN -3 - ONE ANALOGS

Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular proliferation, such as breast cancer.

THERAPEUTIC COMPOUNDS

This invention relates to a novel class of substituted amino-ethoxy benzene derivatives of formula (I) which are inhibitors of serine proteases and to their use in treating aberrant serine protease activity in a mammal, contraception, anti-coagulant methods and methods for treating aberrant cell proliferation, tumours, cancer, angiogenesis, angiogenesis-based retinopathies, autoimmummune disease, inflammation, skin disease, arthritis, rheutmatoid arthritis, asthma, osteoarthritis and multiple sclerosis. (I), Wherein Rm, Rn, Rp, Rq, V, W, X, Y and R8 are as defined in the claims.